UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic cancer, provided a business update and reports financial results for the year ended December 31, 2019. Sun BioPharma is developing SBP-101, a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance to cell function in multiple tumor types, including pancreatic cancer.
“I am delighted with the progress we have made in advancing the development of SBP-101 for patients with metastatic pancreatic cancer. In the past 12 months, we have completed enrollment in the four dose-escalation cohorts of our current trial, presented interim data at the ASCO GI Cancer Symposium, initiated two new clinical sites in the United States, and opened an expansion cohort to patient enrollment at what we believe to be the optimal dose and schedule,” said Michael T. Cullen, MD, MBA, chairman and CEO of Sun BioPharma. “We look forward to completing the design of a randomized phase 2 study.”Learn more about Sun BioPharma Provides Business Update and Reports Operating Results for FY2019.